VacZine Analytics  
ExpertREACT - PREMIUM

Considerations when commercial modelling a universal influenza vaccine. Published 4th August 2010.

Against the backdrop of a growing and rapidly evolving influenza vaccine market, two of the major manufacturers are now involved with the development of universal influenza vaccines. According to VacZine Analytics meeting the "ideal" vaccine profile could be the most valuable opportunity in the whole R&D pipeline.

PAGES: 2

PREMIUMThis article is available only on a "pay per view" basis or to purchasers of MarketVIEW: Universal influenza vaccines (CAT No: VAMV020)

CAT No: CONTENTS: PRICE*: PURCHASE:
VAER100804 Click here>> GBP 14.99
*Prices quotes are global use and distribution. For UK orders VAT will be added at 17.5%.

Return to main list>> Questions about this article?






© 2010 VacZine Analytics. All rights reserved. Disclaimer | Privacy | Terms and conditions. hosted by chillydomains